10 October 2018 - Cancer will affect almost all New Zealanders at some point in their lives. Given the range of new treatments in the pipeline, PHARMAC works hard to fund the best medicines it can based on the evidence, says Sarah Fitt, Chief Executive.

We all know someone who is, or might be, affected by some form of illness. PHARMAC recognises this is a significant issue for many people, and is acutely aware of their concerns, especially about access to new cancer medicines.

New medicines are constantly being developed, and these are often high-cost. Drug companies often claim their new medicine is significantly better than earlier treatments. This makes PHARMAC’s evidence-based approach to making choices about medicines funding more important than ever. Our job is to assess the evidence and see if the claims stack up.

Read PHARMAC feature